PIK3CA and breast cancer: The PI3K inhibitor alpelisib has been approved for patients with metastatic BC harboring PIK3CA-activating mutations [286] and, in one study, about 20% of patients had bone-only metastases and approximately 70% of patients had at least one BM [287].